A total of 551 participants with peanut allergy, from 4 to 55 years old, took part in the study. One third of the participants were given a placebo, while the other two-thirds were given peanut protein powder (AR101) in increasing amounts until reaching the “maintenance dose”, which was the equivalent of one peanut daily.
Results showed that the treatment with the peanut protein powder resulted in desensitization in children and adolescents who were highly allergic to peanut.
PALISADE Group of Clinical Investigators. (2018). AR101 oral immunotherapy for peanut allergy. New England Journal of Medicine.
Results showed that the treatment with the peanut protein powder resulted in desensitization in children and adolescents who were highly allergic to peanut.
PALISADE Group of Clinical Investigators. (2018). AR101 oral immunotherapy for peanut allergy. New England Journal of Medicine.
